Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

ADVM

Adverum Biotechnologies (ADVM)

Adverum Biotechnologies Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ADVM
DataHoraFonteTítuloCódigoCompanhia
09/05/202417:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ADVMAdverum Biotechnologies Inc
09/05/202417:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADVMAdverum Biotechnologies Inc
09/05/202417:05GlobeNewswire Inc.Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline HighlightsNASDAQ:ADVMAdverum Biotechnologies Inc
03/05/202409:00GlobeNewswire Inc.Adverum Biotechnologies to Participate in Upcoming May Investor ConferencesNASDAQ:ADVMAdverum Biotechnologies Inc
25/04/202417:05GlobeNewswire Inc.Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific MeetingNASDAQ:ADVMAdverum Biotechnologies Inc
18/03/202417:05GlobeNewswire Inc.Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate UpdatesNASDAQ:ADVMAdverum Biotechnologies Inc
04/03/202418:40Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ADVMAdverum Biotechnologies Inc
28/02/202418:05GlobeNewswire Inc.Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
22/02/202417:47Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ADVMAdverum Biotechnologies Inc
21/02/202417:39Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ADVMAdverum Biotechnologies Inc
14/02/202422:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ADVMAdverum Biotechnologies Inc
14/02/202418:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADVMAdverum Biotechnologies Inc
12/02/202410:00GlobeNewswire Inc.Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
08/02/202409:00GlobeNewswire Inc.Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDNASDAQ:ADVMAdverum Biotechnologies Inc
05/02/202409:45GlobeNewswire Inc.Adverum Biotechnologies Announces $127.5 Million Private Placement FinancingNASDAQ:ADVMAdverum Biotechnologies Inc
01/02/202419:30GlobeNewswire Inc.Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024NASDAQ:ADVMAdverum Biotechnologies Inc
29/01/202410:00GlobeNewswire Inc.Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific OfficerNASDAQ:ADVMAdverum Biotechnologies Inc
07/12/202318:05GlobeNewswire Inc.Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula SocietyNASDAQ:ADVMAdverum Biotechnologies Inc
04/12/202318:09Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ADVMAdverum Biotechnologies Inc
28/11/202318:05GlobeNewswire Inc.Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
09/11/202318:05GlobeNewswire Inc.Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline HighlightsNASDAQ:ADVMAdverum Biotechnologies Inc
06/11/202321:52Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ADVMAdverum Biotechnologies Inc
06/11/202310:00GlobeNewswire Inc.Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of DirectorsNASDAQ:ADVMAdverum Biotechnologies Inc
04/11/202318:54GlobeNewswire Inc.Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023NASDAQ:ADVMAdverum Biotechnologies Inc
26/09/202317:05GlobeNewswire Inc.Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 TrialNASDAQ:ADVMAdverum Biotechnologies Inc
21/09/202317:05GlobeNewswire Inc.Adverum Biotechnologies to Participate in Upcoming Investor ConferencesNASDAQ:ADVMAdverum Biotechnologies Inc
05/09/202317:05GlobeNewswire Inc.Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
21/08/202317:05GlobeNewswire Inc.Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology OfficerNASDAQ:ADVMAdverum Biotechnologies Inc
14/08/202309:00GlobeNewswire Inc.Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
10/08/202317:05GlobeNewswire Inc.Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial ResultsNASDAQ:ADVMAdverum Biotechnologies Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ADVM